Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) have received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $17.00.
A number of analysts recently weighed in on XERS shares. Oppenheimer reissued an “outperform” rating and issued a $21.00 price objective (up from $18.00) on shares of Xeris Biopharma in a research report on Friday, November 6th. HC Wainwright boosted their target price on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Leerink Partners boosted their target price on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, November 4th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a report on Friday, November 6th.
View Our Latest Report on XERS
Xeris Biopharma Stock Up 0.2%
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 147.75%. On average, analysts predict that Xeris Biopharma will post 0.15 earnings per share for the current year.
Insider Activity at Xeris Biopharma
In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total value of $312,250.00. Following the sale, the insider owned 1,559,208 shares in the company, valued at $19,474,507.92. This trade represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $51,150.00. Following the sale, the insider owned 1,346,053 shares of the company’s stock, valued at approximately $13,770,122.19. This trade represents a 0.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 168,332 shares of company stock worth $1,678,971 in the last quarter. 4.35% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 4.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,657,929 shares of the company’s stock worth $15,850,000 after buying an additional 63,857 shares during the period. Entropy Technologies LP lifted its holdings in Xeris Biopharma by 453.8% during the 3rd quarter. Entropy Technologies LP now owns 161,586 shares of the company’s stock valued at $1,545,000 after buying an additional 132,406 shares in the last quarter. Jump Financial LLC purchased a new stake in Xeris Biopharma in the 3rd quarter valued at about $1,674,000. Marshall Wace LLP purchased a new stake in Xeris Biopharma in the 3rd quarter valued at about $2,802,000. Finally, Bleakley Financial Group LLC purchased a new stake in Xeris Biopharma in the 3rd quarter valued at about $207,000. 42.75% of the stock is currently owned by institutional investors.
About Xeris Biopharma
Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.
Featured Stories
- Five stocks we like better than Xeris Biopharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
